title: Efficacy and safety of and patient satisfaction with injectable hyaluronic acid with 0.3% lidocaine hydrochloride for the treatment of superficial perioral lines or superficial lateral canthal lines.
abstract: BACKGROUND
  It is commonly requested that perioral and lateral canthal rhytides, which result from extrinsic and intrinsic factors, be rejuvenated.
  
  
  OBJECTIVE
  To valuate the safety and efficacy of and patient satisfaction with injectable hyaluronic acid (HA) with 0.3% lidocaine hydrochloride in reducing superficial, vertical perioral wrinkles and superficial, horizontal, lateral canthal rhytides.
  
  
  METHODS
  This was a two-center, evaluator-masked, 180-day study in which 40 patients with moderate to severe superficial, vertical perioral lines or superficial, horizontal, lateral canthal lines were treated at their baseline visit with up to three 0.9-mL syringes of HA (5.5 mg/mL) with 0.3% lidocaine hydrochloride. The investigator and a blinded evaluator assessed patients 7 days after treatment and then every 30 days after the initial treatment session for 180 days.
  
  
  RESULTS
  Subjects experienced statistically significant improvement in their superficial, vertical perioral lines and superficial, horizontal, lateral canthal lines and maintained those results for 180 and 120 days, respectively. Three patients experienced delayed-onset periocular nodule formation associated with swelling and erythema at sites of injection, which were histologically consistent with a granulomatous reaction to the product.
  
  
  CONCLUSIONS
  Injectable HA with a particle size of 350 μm was efficacious and resulted in high patient improvement scores in improving moderate to severe superficial, vertical perioral lines and superficial, horizontal, lateral canthal lines. Three of the 40 enrolled patients demonstrated granuloma formation.
authors.affiliation: Goldman, Butterwick, Fitzpatrick, Groff & Fabi, Cosmetic Laser Dermatology, San Diego, California; Department of Dermatology, University of California at San Diego, San Diego, California; Department of Medicine, University of California at San Diego, San Diego, California.
authors.forename: Sabrina G
authors.initials: SG
authors.lastname: Fabi
authors.forename: Jason P
authors.initials: JP
authors.lastname: Champagne
authors.forename: Kartik D
authors.initials: KD
authors.lastname: Nettar
authors.forename: Corey S
authors.initials: CS
authors.lastname: Maas
authors.forename: Mitchel P
authors.initials: MP
authors.lastname: Goldman
mesh_terms: D000328:Adult; D000368:Aged; D001672:Biocompatible Materials; D003357:Cosmetic Techniques; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D005782:Gels; D006099:Granuloma / Q000139:chemically induced; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D007267:Injections; D008012:Lidocaine / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D010316:Particle Size; D017060:Patient Satisfaction; D016037:Single-Blind Method; D015595:Skin Aging / Q000187:drug effects*; D016896:Treatment Outcome
chemical_list: D001672:Biocompatible Materials; D003879:Dermatologic Agents; D005782:Gels; D006820:Hyaluronic Acid; D008012:Lidocaine